My PD Story

Ross Wilson headshot.
Researchers

Ross Wilson, PhD

2026 Impact Award

Finding the Alpha-Synuclein “Sweet Spot” to Reduce Parkinson’s Risk

A biological trait of Parkinson’s disease (PD) is the accumulation of alpha-synuclein clumps in the brain. Alpha-synuclein is a protein that is important for brain health, but having too much of it increases the chances of clumping occurring. Research suggests that lowering alpha-synuclein levels can be protective, and several therapies aimed at this are currently being developed. However, having too little alpha-synuclein can impair critical brain functions, so maintaining the proper amount in the brain has historically been a challenge. 

Ross Wilson, PhD, recipient of a Parkinson’s Foundation Impact Award, is searching for the alpha-synuclein “sweet spot”— a level high enough that will keep the brain healthy, but low enough to reduce the likelihood of clumping. By using an advanced genetic tool called CRISPR, Dr. Wilson will be able to control the amount of alpha-synuclein produced by brain cells in mice. Doing so will help him and his team uncover the ideal amount that balances normal brain function with PD prevention.

“This research aims to establish a groundbreaking genetic therapy that acts as a long-lasting dimmer switch for the alpha-synuclein gene.” - Dr. Wilson

To efficiently investigate how different brain alpha-synuclein levels affect mice, Dr. Wilson and his team at the University of California, Berkeley, will design gene editing tools that can set the amount produced to roughly 25%, 50% and 75% of normal. They will also have a “knockout” mouse that does not produce alpha-synuclein at all. By observing the behavior of all these mice over time, they can first see how low alpha-synuclein levels can get before it causes problems. 

Then, Dr. Wilson will expose these mice to a toxin that can cause alpha-synuclein clumping and PD-like neurodegeneration. This will help him see if the mice with lower alpha-synuclein levels are able to resist developing PD better than the mice with higher levels. 

Ross Wilson gestures while speaking with colleagues in a laboratory.

Through this research, Dr. Wilson will use different genetic tools that change alpha-synuclein levels in similar ways, creating a robust dataset that will help his team determine ideal alpha-synuclein levels. Importantly, these tools yield long-lasting effects on alpha-synuclein levels, offering the tantalizing prospect of a future “one-time only” genetic therapy for PD. 

Insights from this research could drive the next generation of genetic PD treatments based on reducing PD risk by reducing alpha-synuclein in the brain. By fine-tuning to the alpha-synuclein “sweet spot,” these preemptive treatments could lower a person’s risk for PD with minimal to no impacts on brain function.

“This Impact Award is the first major external validation that our strategy for a PD therapy has real promise,” said Dr. Wilson. “If successful, our research could accelerate the development of similar gene-lowering therapies, both field-wide and for our own novel approach to precisely reducing alpha-synuclein levels in the brain.”

Meet more Parkinson’s researchers! Explore our My PD Stories featuring PD researchers.

Back to Top